Juan Pablo Manrique, Urologic Oncologist at Nueva Granada Military University/National Cancer Institute in Colombia, shared on X:
“Is ctDNA becoming indispensable in muscle-invasive bladder cancer?
KEYNOTE-B15 at ESMO 2026 reinforces its prognostic value and shows higher ctDNA clearance with EV + pembrolizumab (82.1% vs 66.7%). The ? is no longer whether ctDNA matters, but how to integrate it in practice.”
You can also read:
